Zenith Health Care profit falls 92% to ₹0.51 lakhs in FY26
Net profit collapsed from ₹6.70 lakhs the prior year as revenue also slipped. The board reappointed its Joint Managing Director for another three-year term.
What's new
- Net profit crashed 92% to ₹0.51 lakhs in FY26 from ₹6.70 lakhs a year earlier.
- Revenue also declined slightly to ₹10.52 crores.
- Board reappointed Mr. Akshit Mahendra Raycha as Joint MD for three years with a new pay package.
Why this matters
For a company with a market cap of ₹17 crores, annual profit of ₹0.51 lakhs is negligible. The near-total evaporation of earnings in a ₹10.52 crore revenue business points to margin pressure that the annual disclosure alone doesn't explain.
What we're watching
- Whether the Q4 standalone results explain the full-year profit collapse.
- The details of the revised remuneration for the Joint MD.
- Any management commentary on the revenue and margin drivers in the annual report.
The full read
Zenith Health Care's FY26 results are stark. The nano-cap pharma company posted a net profit of just ₹0.51 lakhs on revenue of ₹10.52 crores, a 92% collapse from the ₹6.70 lakhs it earned a year ago. For a business with a market capitalization of ₹17 crores, that level of profit is functionally zero. The filing is a routine annual disclosure, but the scale of the earnings evaporation in a single year demands a clearer explanation than the numbers provided. The board also reappointed Joint MD Akshit Mahendra Raycha with a new pay package, a standard corporate move that will draw more scrutiny given the bottom-line collapse.
Questions answered
- How much did Zenith Health Care's profit fall?
- Net profit dropped 92%, from ₹6.70 lakhs in the prior year to just ₹0.51 lakhs in FY26.
- What happened to revenue?
- Revenue contracted slightly to ₹10.52 crores, though the filing does not provide the prior year's figure for a direct comparison.
- Who is the Joint Managing Director that was reappointed?
- Mr. Akshit Mahendra Raycha was reappointed for another three-year term. The board also approved a revised remuneration package for him, though the details of the new pay were not disclosed in this summary.
- Why is this filing considered routine?
- It is the standard annual audited results disclosure, following a board meeting that had been previously announced. The rationale notes such filings are for regulatory compliance and internal model updates rather than major market surprises.